KR20240103034A - Tigit 및 pd-l1에 대한 이중특이적 항체, 그의 의약 조성물, 및 그의 용도 - Google Patents
Tigit 및 pd-l1에 대한 이중특이적 항체, 그의 의약 조성물, 및 그의 용도 Download PDFInfo
- Publication number
- KR20240103034A KR20240103034A KR1020247019886A KR20247019886A KR20240103034A KR 20240103034 A KR20240103034 A KR 20240103034A KR 1020247019886 A KR1020247019886 A KR 1020247019886A KR 20247019886 A KR20247019886 A KR 20247019886A KR 20240103034 A KR20240103034 A KR 20240103034A
- Authority
- KR
- South Korea
- Prior art keywords
- tigit
- antibody
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111359665.8 | 2021-11-17 | ||
| CN202111359665.8A CN116135884A (zh) | 2021-11-17 | 2021-11-17 | 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 |
| PCT/CN2022/132422 WO2023088337A1 (zh) | 2021-11-17 | 2022-11-17 | 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240103034A true KR20240103034A (ko) | 2024-07-03 |
Family
ID=86332938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247019886A Pending KR20240103034A (ko) | 2021-11-17 | 2022-11-17 | Tigit 및 pd-l1에 대한 이중특이적 항체, 그의 의약 조성물, 및 그의 용도 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250019436A1 (https=) |
| EP (1) | EP4435010A4 (https=) |
| JP (1) | JP2024542192A (https=) |
| KR (1) | KR20240103034A (https=) |
| CN (2) | CN116135884A (https=) |
| AU (1) | AU2022389530A1 (https=) |
| CA (1) | CA3238571A1 (https=) |
| WO (1) | WO2023088337A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121712807A (zh) * | 2023-08-31 | 2026-03-20 | 江苏恒瑞医药股份有限公司 | Ctla4/tigit结合蛋白及其医药用途 |
| TW202544031A (zh) * | 2024-02-29 | 2025-11-16 | 南韓商柳韓洋行股份有限公司 | 抗tigit/抗pd-l1雙特異性抗體及其用途 |
| CN117924510B (zh) * | 2024-03-21 | 2024-06-04 | 北京星基贝勤生物科技有限公司 | 靶向egfr和axl的双特异性抗体及其药物偶联物与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CA2994858C (en) * | 2015-09-25 | 2024-01-23 | Genentech, Inc. | Anti-tigit antibodies and methods of use |
| IL272227B2 (en) * | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| CN112480253B (zh) * | 2019-09-12 | 2022-09-20 | 普米斯生物技术(珠海)有限公司 | 一种抗pd-l1纳米抗体及其衍生物和用途 |
| CN113461824A (zh) * | 2020-03-31 | 2021-10-01 | 普米斯生物技术(珠海)有限公司 | 一种构建多特异性抗体的平台 |
| CN117794952A (zh) * | 2021-08-09 | 2024-03-29 | 普米斯生物技术(珠海)有限公司 | 抗tigit抗体及其用途 |
| CN116925222A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
| CN116925233A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
-
2021
- 2021-11-17 CN CN202111359665.8A patent/CN116135884A/zh active Pending
-
2022
- 2022-11-17 CN CN202280075442.5A patent/CN118251419A/zh active Pending
- 2022-11-17 JP JP2024529415A patent/JP2024542192A/ja active Pending
- 2022-11-17 WO PCT/CN2022/132422 patent/WO2023088337A1/zh not_active Ceased
- 2022-11-17 EP EP22894869.1A patent/EP4435010A4/en active Pending
- 2022-11-17 US US18/711,482 patent/US20250019436A1/en active Pending
- 2022-11-17 AU AU2022389530A patent/AU2022389530A1/en active Pending
- 2022-11-17 CA CA3238571A patent/CA3238571A1/en active Pending
- 2022-11-17 KR KR1020247019886A patent/KR20240103034A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023088337A1 (zh) | 2023-05-25 |
| CA3238571A1 (en) | 2023-05-25 |
| CN116135884A (zh) | 2023-05-19 |
| US20250019436A1 (en) | 2025-01-16 |
| EP4435010A4 (en) | 2025-11-19 |
| CN118251419A (zh) | 2024-06-25 |
| JP2024542192A (ja) | 2024-11-13 |
| EP4435010A1 (en) | 2024-09-25 |
| AU2022389530A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12234286B2 (en) | Anti-TIGIT antibodies and their use as therapeutics and diagnostics | |
| JP2022130393A (ja) | 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用 | |
| US20240352153A1 (en) | Pharmaceutical composition and use | |
| US20250019436A1 (en) | Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof | |
| JP7780521B2 (ja) | 抗ｔｉｇｉｔ抗体、その医薬組成物及び用途 | |
| EP4506365A1 (en) | Anti-tigit/anti-pvrig bispecific antibody, and pharmaceutical composition and use thereof | |
| EP4506360A1 (en) | Anti-pvrig antibody, pharmaceutical composition thereof and use thereof | |
| JP2024538669A (ja) | 抗ｌａｇ３二重特異性抗体、医薬組成物、及び使用 | |
| JP2025524390A (ja) | 抗ｃｌｄｎ１８．２抗体並びにその医薬組成物及び使用 | |
| JP2025511356A (ja) | Ｐｄ－ｌ１及びｃｄ４０を標的とする抗原結合タンパク質及びその製造と応用 | |
| JP2026508210A (ja) | ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用 | |
| HK40093009A (en) | Anti-tigit antibody, and pharmaceutical composition and use thereof | |
| EA049283B1 (ru) | Антитело к tigit и его фармацевтическая композиция и применение | |
| HK40116729A (zh) | 包含TGF-βRII胞外区片段的融合蛋白、其药物组合物及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |